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Cytomegalovirus (CMV) is one of the most common infectious agents, infecting the general population at an early age without
causing morbidity most of the time. However, on particular occasions, it may represent a serious risk, as active infection is
associated with rejection and disease after solid organ transplantation or fetal transmission during pregnancy. Several methods
for CMV diagnosis are available on the market, but because infection is so common, careful selection is needed to discriminate
primary infection from reactivation. This review focuses on methods based on CMV-specific T cell reactivity to help monitor the
consequences of CMV infection/reactivation in specific categories of patients. This review makes an attempt at discussing the pros
and cons of the methods available.
1. Introduction
Cytomegalovirus (CMV) infects roughly 50% of the pop-
ulation in industrialized countries by adulthood. In devel-
oping countries, infection rate is much higher, leaving
few adults seronegative [1]. Most new infections do not
reach clinical relevance, but in specific instances CMV
may represent a risk. For instance, rejection after trans-
plantation may be associated with CMV infection or reac-
tivation. In addition, transmission of CMV to fetus dur-
ing pregnancy is one of the most frequent causes of
deafness, to name but one of the consequences possible
[2]. For different reasons, in both of these situations, it
is quite relevant to assess whether CMV viremia is due
to new infection or reactivation of latent CMV. Several
methods for CMV diagnosis are available on the market,
spanning almost the whole range of possible formats [3].
Certain methods may be useful to discriminate between
primary infection or reactivation. To help assess the real
risk of severe disease posed by CMV, determination of
T cell reactivity is being evaluated by several clinical
researchers.
2. CMV Pathology
CMV belongs to Herpesviridae and is the prototype of the
Betaherpesvirinae subfamily group. It is a ubiquitous virus
that infects a large percentage of humans worldwide, often
at an early age. CMV spreads through a variety of ways,
and virus is persistently expressed in epithelial cells resulting
in virus excretion in bodily fluids, with infected saliva as
its preferential vehicle. Other vehicles include breast milk,
urine, genital secretions, and other body fluids, to a lesser
extent.
As all members of this family, CMV establishes latent
infection in specific body districts after primary infection,
specifically in monocytes and bone marrow CD34+ myeloid
progenitor cells. Viral reactivation occurs from time to
time, under the influence of numerous factors. Latency is
regulated by a variety of specific genes in the virus genome.
However, CMV is thought to persist also due to its many
ways of evading the host immune defenses [4, 5]. Several
viral proteins, such as interleukin 10 homolog and others,
create an immunosuppressive environment around infected
cells that avoids elimination of the latently infected cell by
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the immune system [6]. Virus expression is kept under the
control of the immune system. CD4+ T cells are considered
key elements, as proven by the enormous reduction in the
rate of CMV-related disease in HIV patients after the intro-
duction of the highly active antiretroviral therapy (HAART)
[7].
In the immunocompetent host, primary infection is
almost always subclinical. However, symptoms resembling
infectious mononucleosis by EBV can occasionally be
present. Typically,most of the population gets infected during
childhood and for this reason children in childcare are
a population at risk of infection by exposure to saliva-
contaminated objects. Primary infection is followed by viral
excretion in urine and other body fluids for over 6 months
[8]. Viremia drops when CMV-specific CD4+ T cells peak
[9].
Vertical transmission of infection from a mother with
active infection to the fetus is a cause of concern. Between
0.2% and 2% of newborns are infected with CMV in utero
or perinatally and, of these, approximately 10% develop
clinically evident disease [1, 10]. Approximately 90% of
symptomatic newborns and 15% of the asymptomatic ones
experience long term sequelae [11]; nowadays, CMV is the
most common cause of hearing and neurological impairment
due to nongenetic causes [10].
The risk of infection for a fetus of an actively infected
mother has long been considered to depend on whether the
mother has primary infection or reactivation [12]. Pregnant
women with primary infection have higher chances of trans-
mission during pregnancy, with a frequency of transmission
of roughly a third [11]. Because in developed countries
seroprevalence for CMV ranges between 40% and 60%,many
women are at risk of acquiring primary CMV infection
during pregnancy. The presence of antibodies is considered
a factor that decreases both the risk of transmission of CMV
during reactivation to the fetus and the chances of serious
long term consequences of infection. Indeed, the risk of
transmission drops to 1.4% as a consequence of reactivation
during pregnancy [13]. Nevertheless, in developing countries,
where almost everybody is seropositive for CMV, prevalence
of congenital CMV infection ranges between 1% and 5%
of births. Therefore, recently, reactivation of maternal CMV
infectionwas recognized as being responsible for themajority
of congenital CMV infections [14].
Contrary to the immunocompetent host, CMV infection
often has serious consequences in the immunocompromized
host. For solid organ transplantation (SOT) recipients, the
risk of serious disease varies according to whether recipients
are seropositive or not: patients who are seronegative before
transplantation have a 40 to 80% risk of acquiring primary
CMV infection from the graft [15, 16]. In these patients,
CMV infection increases the risk of superinfection by many
pathogens, and,most importantly, they are likelier to undergo
graft rejection. On the other hand, patients who are seropos-
itive before transplant are at a lesser risk of infection by
the graft, but CMV reactivation may still have serious con-
sequences when they are under immunosuppressive drugs.
For these reasons, transplanted patients routinely undergo
preemptive antiviral prophylaxis for at least 3 months after
transplant, although a period of 6 months is recommended
[17].
HIV patients, another category of immunocompromized
patients,may experience retinitis, gastrointestinal and central
nervous system end organ disease, and pneumonia due to
CMV reactivation [18, 19]. The frequency of such events has
been greatly reduced by HAART therapy.
3. Immune Response to CMV
A very large number of viral proteins are encoded by the rel-
atively complex CMV genome. A total of 751 translated ORFs
were recently identified by several experimental approaches,
including next generation sequencing and high-resolution
proteomics [20].
CMV infection activates robust responses to many of
these proteins by the adaptative and innate immune system,
but it has been somewhat hard to define proper correlates of
immune protection.
Upon primary CMV infection, the earliest antibody
response is directed against tegument protein [21]. Neutral-
izing antibodies are mounted after at least 2 months from
infection and are directed against a number of envelope
proteins, such as the gH/gL/UL128-131A complex and gB, gH,
and gM/gN [22].
Antibodies have a relevant protective role during infec-
tion, in terms of both disease transmission and severity.
Their presence in maternal blood has long been considered
to lower the chances of fetal infection [12]. However, it is
not clear to what extent antibodies are protective since their
presence in maternal milk does not prevent transmission
of infection to babies [23, 24]. In addition, a recent clinical
trial aimed at studying fetal transmission of CMV infection
by pregnant women with primary infection showed that
infusion of hyperimmune globulin did not seem to prevent
transmission to fetus [25].
One can conclude that antibody titer is a correlate of
protection, but the causative link remains elusive. The fact
that some women with high neutralizing Ab titers still
transmit virus to their fetus and that pregnant women can
be reinfected despite vigorous neutralizing antibody titers
indicates that these responses do not absolutely prevent
infection, although they undoubtedly reduce the potential for
infection [12]. Recently, it has been shown that kinetics of
antibody responses to different CMV targets are markedly
different [26, 27]. These results make it tempting to spec-
ulate that the interplay between viral replication and the
development of antibodies to very specific targets might be
more relevant compared to the entire anti-CMV antibody
titer.
Antibody titers may reflect the entity of CD4+ T cell
responses, since they depend on T cell help in a stringent
way. Indeed, very recent data onMacacus rhesus demonstrate
that protection of the fetus from vertical transmission of
CMV infection depends on CD4+ T cells [28]. Whether this
depends on CD4+ T cells directly or indirectly is still to be
clarified. InMacacus, a lower titer of neutralizing antibodies,
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in spite of a normal antibody titer, was observed in the
absence of adequate T cell help [28].
It has been known for more than 20 years that helper
and killer T cells are also expanded at extraordinarily high
frequencies during CMV infection. Although CD4+ T cells
seem to react preferentially against structural viral proteins
and CD8+ T cells react mostly against immediate early ones,
many proteins are recognized by both [29, 30]. Certain
viral proteins are immunodominant, especially pp65 and
IE-1; however, not all antigens seem to induce protective
immunity. For example, it was shown that developing high
frequencies of CD8+ T cells against IE-1, but not against
pp65, early after transplantation is associated with protection
from CMV disease [31]. These data are quite controversial,
as they were not confirmed by several subsequent studies
[32].
CMV-specific CD8+ T cells have long been known to be
key in controlling viral replication in infected hosts and their
adoptive transfer has proven therapeutical in transplanted
patients [33, 34]. Though underestimated in the past, such
T cell-mediated response seems to be quite relevant in the
infected fetus as well [23]. A very recent study performed
on pregnant women with primary CMV infection who either
transmitted or did not transmit CMV to their fetus showed
that proliferative ability of both CD4+ and CD8+ T cells and
IL-2 secretion by CMV-specific CD4+ T cells are lower in
women who transmit CMV [35].
Repeated reactivation of CMVprogressively enhances the
number of CMV-specificCD8+ T cells, which can accumulate
in time up to 20% of total CD8+ T cells, in what is known as
“memory inflation” [36]. CD4+ T cells are also expandedwith
similar kinetics, though to a lesser extent [37]. Interestingly,
proteins expressed during latency are also recognized by T
lymphocytes but these seem to quench immune reactivity
rather than having an effector role [29].
𝛾𝛿+ T cells are also expanded during CMV infection in
the adult and in the fetus [38], where expansion of V𝛿2−𝛾𝛿+
T cells was shown to be a specific blood signature of CMV
infection [39]. Notably, 𝛾𝛿+ cells were proven to have a
protective activity in SOT patients and in early life [23, 38].
Natural killer cells have long been known to be critical in
recovery from CMV infection, both in adult and in fetal life
[23]. As part of innate immunity, they have been shown to
rapidly increase in primary infection until roughly 2 months
after infection and then to decrease [35]. They have recently
been demonstrated to be more similar to the adaptive arm of
the immune system than first thought. Indeed, they seem to
undergo some selection similarly to T cell development in the
thymus; in addition, although they do not undergo somatic
rearrangement of their receptor genes, they have been shown
to expand in an antigen-specific fashion and establish a pool
of “memory” cells in the mouse [40].
In humans, Ro¨lle et al. showed that expansion of specific
NK cell subsets during CMV infection occurs in an MHC-
dependent way and relying on CD94 and NKG2C on NK
cells and HLA-E and IL-12 derived by monocytes, although
the antigen, if there is a specific one, is still unknown [41].
In turn, CMV devotes at least 6 ORFs to counteracting NK
activity, although this is not their only function [42]. This
underlines how important NK cells are in recovering from
CMV infection.
To sum up, both humoral and cellular immune responses
contribute to protection from CMV infection reactivation
and to recovery. However, the specific role of each of the two
arms of the immune response has not been defined, nor have
the interactions of the two components. This consideration
paves the way to future studies where antibody-dependent
cellular cytotoxicity will have to be deeply investigated.
4. Most Commonly Used Methods Available
for CMV Diagnosis: A Brief Overview
Because the consequences of CMV infection vary in different
types of patients and treatment is readily available, it is impor-
tant to diagnose active CMV infection. In many instances,
the most important diagnostic questions are whether CMV
viremia is due to primary infection or reactivation and what
the chances of serious disease are. CMV infection can be
diagnosedwith practically all availablemethods in laboratory
diagnostics, but different clinical questions can be solvedwith
careful choice.
In the case of primary infection in adults, the search
of serum antibodies is first choice to determine whether
adults with infectious mononucleosis symptoms or pregnant
women who have been exposed to CMV have been recently
infected by CMV. CMV-specific antibodies can be deter-
mined by enzyme-linked immunosorbent assay (ELISA) in
various formats as a first choice. ELISA can also be used to
search for IgM [3].
The presence of CMV-specific IgM with low-titer and no
IgG characterizes primary infection. Because IgM tends to be
present also during reactivation, IgG is often found together
with IgM; IgG-avidity tests may therefore be useful tools to
differentiate primary infection from reactivation. As for other
pathogens, avidity of IgG binding CMV increases with time
from infection. When low, this index identifies recent CMV
infection as opposed to reactivation [43].
In pregnant women, it is important to determine the risk
of transmitting CMV infection to the fetus in utero, besides
the occurrence of infection itself. Studies have shown that,
surprisingly, cellular immunity is directly correlated to the
risk of transmission [44, 45].
Direct determination of the presence of CMV virions
is first choice in the diagnosis of CMV infection in the
newborn and fetus, where maternal antibodies may render
serology cumbersome. While intrauterine infection can be
diagnosed by sampling amniotic fluid, newborns shed CMV
inmost body fluids, such as urine and saliva for months [46].
Isolation of CMV may be attempted by classical or shell-vial
cell culture methods. This method has several drawbacks,
above all the fact that CMV grows slowly and some clinical
isolates do not easily adapt to culture conditions, thus leading
to false negative results.
Molecular methods have largely replaced cell culture in
many laboratories. Most of these are based on nucleic acid
amplification of CMVDNA from blood, urine, bronchoalve-
olar lavage fluid, and other body fluids. Modern quantitative
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molecular methods mostly rely on real-time PCR for clinical
viral load testing. Recently, digital droplet PCR (ddPCR) was
evaluated as a method allowing precise direct quantification
without requiring a calibration curve [47, 48]. It relies on
limiting partition of the PCR volume in a large number of
droplets, each of which may be envisioned as a PCR reaction
giving a positive or negative result according to whether a
single targetmoleculewas present in the droplet or not.When
compared to quantitative real-time PCR, ddPCR proved to
reduce quantitative variability but was not as sensitive as real-
time PCR [48].
These methods are more expensive than cell culture but
are much faster and more sensitive. In addition, they may
be rendered quantitative and are relatively independent of
sample deterioration. Determination of T cell immunity may
be helpful diagnosing infection in children younger than 12
months [49, 50].
Finding CMV-specific IgM in fetal and newborn serum
may also be used to diagnose infection.
Consensus guidelines have been set for the management
of SOT patients [17]. Before transplantation, CMV IgG
should be determined in patients and donors because CMV−
recipients transplanted with tissues from CMV+ donors are
at high risk of primary CMV infection. To discriminate
equivocal serology results, it may be useful to assess cellular
immune status against CMV. After transplantation, active
disease, whether primary or due to reactivation, should
be closely monitored by determining viral load. Classically,
this has been carried out by the pp65 antigenemia test:
purified peripheral blood leukocytes (PBLs) frompatients are
enumerated at UV microscope after staining with anti-CMV
nuclear protein pp65 fluorescent monoclonal antibodies. A
semiquantitative result of the number of PBLs with infected
nuclei out of 200,000 is obtained. However, neither inter-
laboratory standard is available nor has common agreement
on cutoff values been reached for this test. Most laboratories
have replaced determination of antigenemiawith quantitative
determination of viral DNA load in whole blood or plasma.
Although a plasma DNAemia cutoff value of
10,000 copies/mL has been suggested before CMV therapy
is started [51], a consensus has not been reached and cutoffs
differ between laboratories. A WHO standard to calibrate
diagnostic tests is now available [17]. Serology is not helpful
in posttransplant patients, where negative results may be due
to immune suppression.
5. Diagnostic Methods Based on
T Cell Reactivity
While the presence of CMV-specific IgG has been long
considered the golden standard to define infection by CMV,
it has been proposed that measuring CMV-specific T cell
responses by specific assays might help predict whether a
patient will develop serious CMV disease after transplant.
Improving criteria to treat patients for active CMV infection
would avoid unnecessary treatment and related toxicity and
allow saving the costs of repeated monitoring of CMV
reactivation and of prophylaxis. Although at present it is
not routinely performed, monitoring cell immunity to CMV,
alone or in parallel to viral load determination, may help
identify patients that actually require treatment for CMV
disease after transplantation and/or help set personalized
cutoff values for CMV DNAemia or antigenemia for patients
at high or low risk of CMV disease, that is, with low or high
T cell responses to CMV, respectively.
CMV-specific T cell reactivity before transplantation,
and not so much seropositivity, was shown to inversely
correlate to the risk of CMV viremia and disease after trans-
plant; spontaneous clearance of CMV may occur in patients
with positive CMV DNAemia or antigenemia, especially in
patients where robust T cell immunity can be detected against
CMV, independently of their serological status against CMV
[52].
In the past years, different techniques have been
developed to detect antigen-specific T cell response: flow
cytometry-based multimer or intracellular cytokine staining
(ICS) and ELISpot have been employed in research and in
clinical studies [53, 54]. The advantages and disadvantages of
each technique have been highlighted in a comparative study
[55].
ICS for CMV-specific T cells followed by flow cytometry
is particularly useful in basic research [54].This assay consists
of a 4–6 h stimulation of PBL or whole blood with CMV
antigen, costimulatory antibodies, and a secretion inhibitor
like Brefeldin A. This is followed by fixation, permeabi-
lization, and staining with antibodies against an intracellu-
larly retained cytokine, most commonly IFN𝛾, and surface
markers like CD4, CD8, and others of interest, labeled with
different fluorophores. FACS analysis is then performed. The
assay allows enumeration of CMV-specific T cell subsets and
simultaneously permits determination of the phenotype of
single cells and the cytokines they produced after stimulation.
ICS is a very informative test because it allows the detection
of both CD8+ and CD4+ antigen-specific T cells in a single
assay. A broad spectrum of different phenotypic markers and
cytokines can also be analyzed at the same time [54]. Itmay be
useful to detect immune responses also in samples of patients
who lack response against particular dominant epitopes in
their pathogen-specific T cell repertoire [56]. However, ICS
requires a good level of expertise and is labour intensive, in
addition to being costly.
A variation of the ICS can be carried out by the use of
tetramers of MHC class I and CMV-derived peptide, used
in ICS both as stimulants of specific CD8+ T cells and as
fluorescent labels [53]. Recently, this technique was used in
an effort to define cutoff values of CMV-specific CD8+ T cell
in allogeneic hematopoietic stem cell transplant recipients
associated with protection from recurrent or persistent CMV
infection. Recovery fromCMVdiseasewas shown to be faster
when these cells were ≥ 7 cells/𝜇L of blood during the first 65
days after transplantation, whereas a value < 7 cells/𝜇L was
indicative of CMV-related complications [57].
More recently, the tetramers technique have been
improved by using “multimers” which have higher affinity
for the T cell receptor (TCR) compared to tetramers and
guarantee more stable binding. Multimer staining allows
labeling, visualization, and enumeration of peptide-specific
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T cells in patient peripheral blood samples. Even if this test
requires a small amount of blood sample and the results are
available within 3 hours, it is not suitable as a diagnostic
tool, because several multimers are required to obtain a
full overview of the immune response for each patient.
Furthermore, due to MHC polymorphism, a multimer for
each single HLA allele would be necessary [58].
Because of their complexity, both methods are limited to
research activities.
An ELISPOT-based method to determine cellular im-
mune reactivity against CMV was developed by Oxford
Immunotec. It uses a mixture of peptides derived from
CMV antigens IE-1 and pp65 that stimulate IFN𝛾 secretion
by both CD4+ and CD8+ T cells from purified PBL. Indi-
vidual IFN𝛾-producing cells are enumerated out of a total
of 200,000 PBLs placed in each ELISPOT well coated with
antibodies capturing secreted IFN𝛾. Controls include un-
stimulated (negative) and phytohemagglutinin- (PHA-) stim-
ulated (positive) cells.
ELISPOT allows discriminating between low respond-
ers (20–50 spots/106 PBLs) and high responders (>100 spots/
106 PBLs) in 2 days from blood sampling [59]. This assay was
shown to be useful to predict the risk of CMV reactivation
and infection in hematopoietic and kidney transplant recipi-
ents, since strong cell immunity is predictive of less serious
CMV disease [60, 61]. This assay was also used to show
that higher values of cell-mediated immunity in the blood
of pregnant women are associated with risk of fetal CMV
transmission [44, 62]. This surprising observation might be
due to the fact that the number of specific T cells increases
with viremia. However, experimental data do not agree with
these findings and demonstrate that the number of CD4+ T
cells correlates with protection [28].
The assay linearity has been shown to be comparable to
ICS [55] but ELISPOT for CMV-specific T cells was shown to
be more sensitive than ICS [63].
ELISpot is, so far, themost sensitivemethod to determine
T cell frequencies, but it is costly and laborious and, above all,
it is hard to standardize for clinical purposes because ranges
of frequencies vary greatly in the general population.
QuantiFERON-CMV (QT, Qiagen) is an assay that meas-
ures IFN𝛾 release after stimulation of CD8+ T cells in whole
blood with a cocktail of peptides binding a range of different
HLA-I haplotypes, designed on the basis of a variety of
CMV proteins. Again, controls are stimulation with phyto-
hemagglutinin or no stimuli [64]. One mL of heparinized
whole blood is incubated for 15–24 h, and then IFN𝛾 content
is measured in plasma by ELISA. It is CE marked (i.e.,
approved by the European Community and legally placed
on the market in Europe) for clinical diagnostic use in
Europe but not yet FDA approved in the United States.
The assay yields positive and negative results when >0.2 or
<0.2 International Units (IU) of IFN𝛾/mL, respectively, is
recovered from CMV-stimulated supernatants. The result is
obtained after subtraction of the value of the unstimulated
sample and only if the value in PHA-stimulated blood is
>0.5U/mL. In addition, an indeterminate result can be
obtained when no IFN𝛾 can be found in the CMV or in the
PHA-stimulated blood, where patients have low numbers of
PBLs. The advantage of QT is its ease in clinical application,
requiringminimal sample processing and technical expertise.
However, the determination of IFN𝛾 release by CD8+ T cells
alone may be a limitation, since CD4+ T cells are as relevant.
In addition, the use of peptides may lead to false negative
results for rare HLA haplotypes.
Positive QT results in the week of the onset of CMV
reactivation or, alternatively, 2 months after allogeneic
hematopoietic stem cell or kidney transplantation were
shown to correlate with a lower risk of complicated reac-
tivation [60, 65]. Among QT-positive patients, roughly 6%
develop CMV disease, versus 22% of QT-negative ones. The
group with the highest risk of CMV reactivation was the
indeterminate group, where 58% of patients developed CMV
disease at 12 months after transplantation [66].
Although QT was shown to be as good as ELISPOT in
determining the risk of CMV infection in kidney transplant
recipients [60], results from QT analysis were not found to
correlate to the risk of transmission of congenital CMV, as
opposed to ELISPOT [44].
Transplant patients with positive results have been shown
to have a reduced risk of CMV reactivation or of severe
disease upon discontinuation of antiviral prophylaxis [65,
67].
QT-CMV was compared to ELISPOT performed with a
CMVpp65 peptidemix (10 𝜇g/mL;AID) inmonitoringCMV
cell immunity in kidney transplant patients. The assays were
shown to display good correlation and similar sensitivities
and specificities [60]. However, both assays in their present
format failed to detect all CMV-reactive individuals and
would profit from improvement of the selected antigen.
Whole CMV virions were proposed to overcome failure of
certain HLA types to bind the mixture of pp65 peptides
[59]. In contrast, another study compared the usefulness of
ELISPOT and that of CMV-QT in predicting transmission
of congenital CMV infection by pregnant women. In this
study, mother CMV-specific T cell frequencies in mothers
determined by ELISPOT, but not by QT, correlated with
congenital CMV, together with maternal viremia and viruria
(𝑝 < 0.05) and correlated negatively with CMV IgG-avidity
(𝑝 < 0.01) [44].
In comparison to ICS, QT is as specific but less sensitive
[68]. However, ICS is definitely more difficult to standardize
and not suitable for automation.
6. Concluding Remarks
CMV infection may represent a risk for transplanted,
immunocompromized, or immunologically immature indi-
viduals. In transplanted patients,measuring viremia levels for
CMV is useful to determine whether the virus has reactivated
due to immune suppression. However, patients may or may
not clear CMV spontaneously, and therefore more detailed
clinical diagnostic tools are warranted to set personalized
cutoffs for antiviral therapy, given that laboratory assays, such
as the determination of antibody titer, isotype, and avidity,
are of limited utility to assess risk of transmission of infection
frommother to fetus. For these reasons, many clinical studies
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have attempted to measure CMV-specific T cell reactivity as
an indicator to predict the outcome of infection in different
clinical situations. Indeed,most studies agree that quantifying
T cell response to CMV can be useful and at least one assay,
QT, has been standardized for clinical diagnostic use. Future
milestones may be as follows: (1) first future milestone is to
extend observations concerning the benefits of determining
T cell reactivity in different clinical situations; (2) second one
is to improve the currently available methods, for example,
by allowing QT to determine CD4+ T cell reactivity besides
CD8. This may be achieved by including whole recombinant
CMV antigens, virions, or defined MHC class II-binding
peptides as stimulators of IFN𝛾 release and may lead to more
reliable and generalized cutoffs for antiviral therapy. (3) The
third future milestone is to adapt methods, that is, CMV
ELISPOT, which may be more sensitive than others, to the
clinical practice.
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